Commenting on the survey by the Independent Pharmacy Federation about Direct-to-Pharmacy supply schemes, Stephen Whitehead, Chief Executive of the ABPI, said:
03 Aug 2011 Posted in ABPI statement By Press Office
"I was concerned to see the results of the recent Independent Pharmacy Federation (IPF) survey about Direct-to-Pharmacy (DTP) supply schemes.
"A number of ABPI members have chosen to move to a DTP model in order to take responsibility of the distribution process and to ensure that UK patients receive the treatments they require. DTP allows manufacturers to keep track of where the medicines they produce are going, secures the supply chain and allows effective trace and recall of products if necessary. There are a number of mechanisms in place to ensure the supply of medicines to patients. UK pharmacists that require support sourcing the medicines they need can find further information from the Pharmaceutical Services Negotiating Committee.
"We encourage the IPF to lend its support to driving adoption of the recent Department of Health guidelines as well as sharing the results and methodology of its survey with us directly so that we may better understand their findings. The ABPI welcomes the opportunity that has been offered by the IPF to discuss this matter and we look forward to opening a constructive dialogue with them shortly to resolve this issue as best as possible. The ABPI has stated previously that current challenges in the supply chain cannot be solved in isolation and will only be addressed by all healthcare partners working collaboratively to find an appropriate solution. The ABPI looks forward to engaging in this with other relevant groups, including the IPF."
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
We represent innovative research-based biopharmaceutical companies, both large and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing 90 per cent of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
We are the Government recognised body negotiating the pricing of branded medicines on behalf of the entire industry. Working with our Research Affiliate Members, we promote the UK as a destination of choice for international life sciences investment.